News >

Novel Treatments Emerging in HER2+ Breast Cancer Pipeline

Danielle Bucco
Published: Monday, Jan 08, 2018

Aleix Prat, MD, PhD

Aleix Prat, MD, PhD
There are a number of novel treatments being developed in the paradigm of HER2-positive breast cancer, according to Aleix Prat, MD, PhD, head of the Department of Medical Oncology at the University of Barcelona.

In a lecture during the 2017 San Antonio Breast Cancer Symposium, Prat highlighted some of these systemic therapies, which include biosimilars, novel chemotherapy modalities, tyrosine kinase inhibitors (TKIs), and more.

ABP 980

A study investigating the efficacy and safety of the biosimilar ABP 980 compared with trastuzumab (Herceptin) in HER2-positive early-stage breast cancer showed clinical equivalence in the neoadjuvant setting. The results further demonstrated similarity between the drugs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication